Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detection in ALL (ESG-MRD-ALL), consisting of 30 MRD-PCR laboratories worldwide, has developed guidelines for the interpretation of real-time quantitative PCR-based MRD data. The application of these guidelines ensures identical interpretation of MRD data between different laboratories of the same MRD-based clinical protocol. Furthermore, the ESG-MRD-ALL guidelines will facilitate the comparison of MRD data obtained in different treatment protocols, including those with new drugs.
van der Velden
V H J
VH
Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.
Cazzaniga
G
G
Schrauder
A
A
Hancock
J
J
Bader
P
P
Panzer-Grumayer
E R
ER
Flohr
T
T
Sutton
R
R
Cave
H
H
Madsen
H O
HO
Cayuela
J M
JM
Trka
J
J
Eckert
C
C
Foroni
L
L
Zur Stadt
U
U
Beldjord
K
K
Raff
T
T
van der Schoot
C E
CE
van Dongen
J J M
JJ
D004273:DNA, Neoplasm / Q000235:genetics; D015321:Gene Rearrangement; D005803:Genes, Immunoglobulin; D006801:Humans; D018365:Neoplasm, Residual / Q000235:genetics*; D016133:Polymerase Chain Reaction / Q000379:methods*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000382:microbiology; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*
D004273:DNA, Neoplasm; D011948:Receptors, Antigen, T-Cell